Teduglutide therapy in a child with short bowel syndrome

Introduction. Short bowel syndrome in children is a rare disease. One of the most common etiological factors for development short atresia small intestine. After surgical correction congenital anomaly, remaining intestine attempts to increase absorption restore homeostasis, and process intestinal adaptation begins. This can be assisted with analogues endogenous growth intestine, such as teduglutide. Case outline. A girl, aged two years eight months, who had an estimated 20 cm after clinical signs syndrome. She was repeatedly hospitalized due frequent need parenteral fluid, electrolyte, nutrient imbalances. Stagnation body weight slow height were accompanied by weakened gross motor strength slowed psychophysical development. exploit conservative treatment measures, stimulation initiated drug 6 months therapy, progress observed parameters, well intelligence quotient abilities. Conclusion. challenging entity every clinician, its previous therapy has mainly consisted substitution nutrients, fluids, electrolytes. Surgical carries risk loss lifelong immunosuppression. The pharmacological possibilities promoting using drugs teduglutide represent light at end tunnel patients